Close
Almac
Achema middle east

Agilent and Tata Institute of Fundamental Research, Hyderabad collaborate to advance scientific frontiers in health and metabolism research

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.
- Advertisement -

In a significant step toward strengthening India’s efforts in nutrition and metabolism research, Agilent Technologies and the Tata Institute of Fundamental Research (TIFR), Hyderabad have announced a strategic collaboration to support ARUMDA (Advanced Research Unit on Metabolism, Development, and Aging). This partnership brings together Agilent’s global expertise in analytical science with TIFR’s research endeavors to address the growing burden of non-communicable diseases (NCDs) and malnutrition in the country.

Agilent and Tata Institute of Fundamental Research Hyderabad MOU Signing

A key outcome of this collaboration is the launch of the Agilent–TIFR Center of Translational Research in Hyderabad. The center will play a pivotal role in supporting the Advanced Research Unit on Metabolism, Development & Aging (ARUMDA)—one of India’s most ambitious government-supported initiatives in human health. ARUMDA is focused on bridging fundamental biology with clinical insights to drive data-driven discovery and inform public health strategies. Agilent’s role centers on enabling this vision through high-performance analytical solutions that support impactful translational research.

This collaboration reflects a shared commitment to advancing science that is rigorous, relevant, and aligned with national health priorities. It is designed to empower researchers with the tools and workflows needed to explore complex biological systems, generate population-specific insights, and translate them into meaningful interventions.

Agilent is contributing to advanced analytical capabilities that support key areas such as molecular profiling, metabolomics, trace element analysis, and cellular bioenergetics. These integrated solutions help researchers navigate the intricacies of human biology and uncover insights that can guide future interventions—particularly in the context of large-scale, population-based studies. This approach reinforces the collaboration’s focus on enabling science that is both data-driven and impactful.

“Our partnership with TIFR reflects Agilent’s commitment to enabling transformative science through technology, collaboration, and shared purpose,” said Nandakumar Kalathil, Country General Manager, Agilent Technologies India. “We are proud to support a project of this scale and ambition—one that aligns with national priorities and has the potential to deliver real-world health impact.”

Prof. M. Krishnamurthy, Centre Director, TIFR Hyderabad, added, “This partnership represents a meaningful step forward in our efforts to translate fundamental research into real-world solutions. The Agilent–TIFR Center of Translational Research will enhance our scientific capabilities and contribute to national efforts in addressing the growing burden of lifestyle-related diseases.”

The collaboration also supports the development of a new analytical facility in Hyderabad, established in partnership with the National Analytical Facility for Research in Nutrition and Metabolism, under the ARUMDA umbrella. Aligned with the National Nutrition Mission, the facility is expected to play a critical role in advancing India’s research capabilities in metabolic health and nutrition science.

By combining deep scientific inquiry with advanced analytical technologies, Agilent and TIFR are helping shape a future where research is more connected, more interdisciplinary, and more responsive to the evolving health needs of society. This partnership also reflects Agilent’s long-standing commitment to supporting India’s scientific ecosystem—enabling innovation that spans academia, public health, and industry.

Latest stories

Related stories

Specialized Laboratory Equipment Requirements for Biologics and Biosimilar Development

The development of complex biological molecules requires a specialized toolkit distinct from traditional small-molecule chemistry. This article details the critical laboratory equipment—from advanced bioreactors to high-resolution characterization tools—that enables the precise engineering and rigorous analysis required for successful biologics and biosimilar innovation.

Next-Generation Laboratory Equipment Redefining Drug Discovery Workflows

Advanced technologies such as AI-integrated high-throughput screening platforms and automated assay systems are fundamentally transforming early-stage pharmaceutical research. These innovations address critical bottlenecks in productivity and data quality, enabling research teams to accelerate timeline-to-candidate selection while enhancing the predictive accuracy of drug discovery campaigns.

Redefining Success Metrics in Pharma Portfolio Management

Shift from traditional R&D metrics focused on milestone completion and budget adherence to outcome-based, value-focused metrics that measure strategic impact, learning velocity, and long-term portfolio health while aligning organizational behavior with strategic objectives.

Smarter Resource Planning for Complex Pharma Development Portfolios

Align limited resources with complex pharmaceutical portfolios through capacity forecasting, skills-based planning, and dynamic resource reallocation, improving execution outcomes without increasing costs or overburdening teams.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access theMedia Pack Now

– Book a Conference Call

Leave Message for Us to Get Back

Translate »